Bessemer Group Inc. Sells 542 Shares of Becton, Dickinson and Company $BDX

Bessemer Group Inc. cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,146 shares of the medical instruments supplier’s stock after selling 542 shares during the period. Bessemer Group Inc.’s holdings in Becton, Dickinson and Company were worth $2,609,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Brighton Jones LLC increased its position in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the last quarter. FORA Capital LLC bought a new position in shares of Becton, Dickinson and Company in the first quarter worth approximately $3,458,000. Cacti Asset Management LLC boosted its stake in Becton, Dickinson and Company by 0.8% in the second quarter. Cacti Asset Management LLC now owns 180,271 shares of the medical instruments supplier’s stock worth $30,801,000 after buying an additional 1,500 shares in the last quarter. Baker Tilly Wealth Management LLC boosted its stake in Becton, Dickinson and Company by 25.4% in the second quarter. Baker Tilly Wealth Management LLC now owns 6,898 shares of the medical instruments supplier’s stock worth $1,188,000 after buying an additional 1,399 shares in the last quarter. Finally, Northside Capital Management LLC purchased a new stake in Becton, Dickinson and Company in the second quarter worth approximately $7,939,000. 86.97% of the stock is currently owned by institutional investors.

Insider Transactions at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares in the company, valued at $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 1,895 shares of company stock valued at $358,995 in the last ninety days. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Price Performance

BDX opened at $181.49 on Thursday. The stock has a fifty day simple moving average of $189.14 and a two-hundred day simple moving average of $183.39. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The company has a market cap of $52.02 billion, a price-to-earnings ratio of 32.64, a price-to-earnings-growth ratio of 1.44 and a beta of 0.25. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. Research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

BDX has been the subject of several research reports. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Piper Sandler reaffirmed a “neutral” rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Argus upped their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.